An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

A Phase 2a Study of BMS-790052 and BMS-650032 in Combination Therapy With Japanese Subjects With Genotype 1 Chronic Hepatitis C (HCV) Virus Infection

To assess the efficacy and safety profile of co-administration of BMS-790052 and BMS-650032 for 24 weeks treatment.

Inclusion Criteria:

• Subjects chronically infected with HCV Genotype 1
• HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening

Exclusion Criteria:

• Subjects with evidence of liver cirrhosis
• Evidence of HCC
• Co-infection with hepatitis B virus, HIV